Predict your next investment

Corporation
HEALTHCARE | Drug Delivery
ensysce.com

See what CB Insights has to offer

Founded Year

2003

Stage

Reverse Merger | IPO

Total Raised

$14.19M

Market Cap

0.06B

Stock Price

2.23

About Ensysce Biosciences

Ensysce Biosciences (NASDAQ: ENSC) (OTC: ENSCW) is focused on the use of fullerene carbon nanotubes for therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr. Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.

Ensysce Biosciences Headquarter Location

7946 Ivanhoe Avenue

La Jolla, California, 92037,

United States

(858) 263-4196

Latest Ensysce Biosciences News

Ensysce Biosciences Announces $15 Million Convertible Note Financing

Sep 27, 2021

09/27/2021 | 08:01am EDT Message : *Required fields SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes (the “Notes”) and warrants exercisable for Ensysce common stock (the “Warrants”) in a private placement for an aggregate investment of $15 million. An initial funding by the Investors occurred on September 24, 2021, for $5 million prior to fees and offering expenses. The Notes are convertible into shares of Ensysce common stock at a conversion price of $5.87, a 30% premium to the base price set at the time of the initial closing. The Notes have a maturity date of 21 months from the applicable closing date and will bear interest from date of issuance at 5.0% per annum, with monthly principal payments in cash or common stock beginning approximately 90 days after the initial closing. The Notes were issued with an original discount of six percent (6%). The Warrants have the right to purchase up to 361,158 shares of common stock at an exercise price of $7.63, a 30% premium to the conversion price. The Warrants are exercisable for five years following the date of issuance. The total gross proceeds from the issuance of the Notes pursuant to the securities purchase agreement, expected to be $15 million before fees and expenses, will be used for general working capital purposes. At the first closing, $5 million of funding was secured. The second closing is expected to occur upon satisfaction of certain conditions, at which time the Company will issue to the institutional investors referenced above, (i) Notes in the aggregate principal amount of $10.6 million for an aggregate purchase price of $10 million and (ii) Warrants to purchase 722,317 shares of the Company’s common stock at an exercise price of $7.63. “This financing marks another step forward in advancing our mission to transform pain treatment and provide a critical solution to the opioid crisis,” said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. “These proceeds complement the funds received upon our merger with Leisure Acquisition Corp and funding available through our federal government grants. This financing should enable us to advance our lead clinical programs, including completion of our PF614-102 bioequivalence study and our nasal and oral human abuse liability studies, as a well as to continue expanding our pipeline of products in the pain, opioid use disorder (OUD) and ADHD space.” A registered broker-dealer is acting as the sole placement agent in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended. About Ensysce Biosciences: Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com . Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Ensysce Biosciences Company Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ensysce Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ensysce Biosciences is included in 6 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

A

Advanced Materials

1,209 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Ensysce Biosciences Patents

Ensysce Biosciences has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/1/2011

7/8/2014

Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/1/2011

00/00/0000

00/00/0000

Grant Date

7/8/2014

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Carbon nanotubes, Nanotechnology, Nanomaterials, Dosage forms, Drug delivery devices

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Ensysce Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ensysce Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.